ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TARA Protara Therapeutics Inc

2.70
-0.05 (-1.82%)
Last Updated: 11:09:04
Delayed by 15 minutes

Period:

Draw Mode:

Volume 93,972
Bid Price 2.69
Ask Price 2.73
News -
Day High 2.795

Low
1.04

52 Week Range

High
5.24

Day Low 2.63
Company Name Stock Ticker Symbol Market Type
Protara Therapeutics Inc TARA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -1.82% 2.70 11:09:04
Open Price Low Price High Price Close Price Prev Close
2.71 2.63 2.795 2.75
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
953 93,972 $ 2.69 $ 252,478 - 1.04 - 5.24
Last Trade Time Type Quantity Stock Price Currency
11:09:21 1 $ 2.71 USD

Protara Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
9.6M 11.43M - 0 -40.42M -3.54 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Protara Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TARA Message Board. Create One! See More Posts on TARA Message Board See More Message Board Posts

Historical TARA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.073.152.632.82166,973-0.37-12.05%
1 Month3.965.242.633.56577,862-1.26-31.82%
3 Months2.435.242.423.60249,6850.2711.11%
6 Months1.575.241.043.19146,3211.1371.97%
1 Year3.045.241.043.1086,947-0.34-11.18%
3 Years15.6215.951.045.8089,374-12.92-82.71%
5 Years25.2067.0791.049.2380,063-22.50-89.29%

Protara Therapeutics Description

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Your Recent History

Delayed Upgrade Clock